China NMPA Drug Inspection - Shijiazhuang Runxiang Traditional Chinese Medicine Pieces Co., Ltd. - Codonopsis pilosula (processed)

The Heilongjiang Provincial Food and Drug Administration (China) issued an announcement on January 11, 2018, detailing findings from drug quality inspections. These inspections, conducted by four drug testing institutions, identified nine batches of unqualified Traditional Chinese Medicine decoction pieces from six different manufacturers. Key companies cited for these issues include Harbin Yutai Pharmaceutical Co., Ltd., Shijiazhuang Yongxin Traditional Chinese Medicine Processing Co., Ltd., Hubei Huanggang Jingui Traditional Chinese Medicine Industry Co., Ltd., Bozhou Baixin Traditional Chinese Medicine Processing Co., Ltd., Sichuan Jiangyou Xinlin Aconitum carmichaelii Pharmaceutical Co., Ltd., and Anhui Yiyuantang Traditional Chinese Medicine Processing Technology Co., Ltd. The primary violations involved critical quality attributes such as appearance (properties), identification, and content determination, indicating non-compliance with standards outlined in the *Chinese Pharmacopoeia 2010* or *2015 Editions*. In response, regulatory authorities immediately implemented control measures, including sealing and seizing the affected products. Sampled units were ordered to suspend sales and usage of the non-compliant batches and initiate rectification. Furthermore, local food and drug administration departments were mandated to investigate any illegal sales activities in accordance with Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*. These departments are required to publicly disclose the handling results for the implicated enterprises within three months and report the relevant information to the Provincial Bureau.